NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- State
- Under way
- Phase
- Phase 3
- People
- 341 taking part
- Started
- 15 Mar 2024
- Primary completion
- 26 Oct 2026
- Arms
- Retatrutide Dose 1, Retatrutide Dose 2, Retatrutide Dose 3
- Results
- None posted
- 7 Mar 2024: Trial registered
- 15 Mar 2024: Trial started